

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines ~~and/or to persons having expression lines, the~~ a composition comprising at least one compound selected from the group consisting of adenosine and adenosine analogues[[, in]] and a physiologically acceptable medium.
2. (Original) The method according to Claim 1, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.
3. (Currently Amended) The method according to Claim 1, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine; toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptapurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-cyclopentyladenosine, 2-chloro-N⁶-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, ~~MECA~~ 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N-ethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, ~~DPMA~~ N⁶-[2-

(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

4. (Original) The method according to Claim 1, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

5. (Original) The method according to Claim 2, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

6. (Original) The method according to Claim 3, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

7. (Cancelled).

8. (Original) The method of Claim 1, wherein said composition comprises adenosine.

9. (Original) The method of Claim 4, wherein said composition comprises adenosine.

10. (Original) The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on contractile fibroblasts.

11. (Original) The method according to Claim 10, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.

12. (Currently Amended) The method according to Claim 10, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptapurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-cyclopentyladenosine, 2-chloro-N⁶-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, ~~MECA~~ 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N-ethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, ~~DPMA~~ N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

13. (Original) The method according to Claim 10, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

14. (Original) The method according to Claim 11, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

15. (Original) The method according to Claim 12, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

16. (Canceled).

17. (Original) The method of Claim 10, wherein said composition comprises adenosine.

18. (Original) The method of Claim 13, wherein said composition comprises adenosine.

19. (Original) The method of Claim 1, wherein said composition comprises adenosine and at least one adenosine analogue.

20. (Original) The method of Claim 10, wherein said composition comprises adenosine and at least one adenosine analogue.

21. (Currently Amended) The method of claim 1, comprising topically applying to the skin an effective amount of said composition to ~~decrease wrinkles and/or~~ reduce laugh lines and/or reduce frown lines.

22. (Currently Amended) The method of claim 8, comprising topically applying to the skin an effective amount of said composition to ~~decrease wrinkles and/or~~ reduce laugh lines and/or reduce frown lines.

23. (Currently Amended) A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines ~~and/or to persons having expression lines, the~~ a composition comprising adenosine in an amount of from 0.01% to 1% by weight with respect to the total composition [[, in]] and a physiologically acceptable medium.